VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington’s disease, announced today a new five-year collaboration focused on discovering novel drugs for Huntington’s disease. Galapagos’ service division BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration. read more
Galapagos NV (Euronext: GLPG) announced today that its Annual General Shareholders’ Meeting (AGM) held on 27 April 2010 approved Dr. Ronald Brus’ appointment to the Board of Directors, as well as all other agenda items of the AGM. Furthermore, the Extraordinary General Shareholders’ Meeting (EGM) held immediately after the AGM approved the creation of a new Warrant Plan for the benefit of the Directors. In addition, the Board of Directors approved the creation of a new Warrant Plan for the benefit of employees and independent consultants of the Company. read more
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ghent University (Belgium) have signed an agreement for the use of Roche´ s LightCycler® 1536 Instrument in various cancer research projects in Ghent. Studies include multigene expression signature profiling on cancer research samples and, digital PCR for sensitive detection of mutant cancer cells in a background of normal cells. Furthermore, DNA methylation analysis studies, copy number variant screening (CNV), and amplicon generation for next generation sequencing are part of the planned experiments. One potentially groundbreaking study is a qPCR based transcriptome-wide profiling, which represents a tremendous undertaking and novel approach in this research area. In a pilot experiment, Ghent University plans to measure all human genes in the four MAQC reference RNA samples. read more
VIB, a life sciences research institute in Flanders, Belgium and Cellectis, (Alternext: ALCLS), the French genome engineering specialist, today announced that they are going to collaborate on research into new approaches to cure haemophilia. Thierry Vandendriessche and Marinee Chuah from the VIB Vesalius Research Center at K.U. Leuven are going to use meganucleases - tailor made enzymes engineered by Cellectis - to replace faulty blood clotting factor genes with functional copies. read more
